PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.79%
Cash & equivalents declining -35.79% while TRAW's grows 36.57%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-35.79%
Below half of TRAW's 36.57%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.27%
Other current assets growth < half of TRAW's 58.57%. David Dodd sees a leaner approach to short-term items.
-32.53%
Below half of TRAW's 35.79%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-2.15%
Below half TRAW's -6.00%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.04%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-1.56%
Similar yoy growth to TRAW's -1.50%. Walter Schloss finds parallel expansions in non-current assets.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
Below half of TRAW's 35.48%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-12.11%
Above 1.5x TRAW's -2.06%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-29.66%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6.29%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
100.00%
Less than half of TRAW's -65.78%. David Dodd sees fewer expansions in other current obligations.
-11.86%
50-75% of TRAW's -16.67%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of TRAW's 55.75%. David Dodd notes more conservative expansions in non-current obligations.
-7.08%
Less than half of TRAW's 0.18%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-11.32%
Similar yoy to TRAW's -11.36%. Walter Schloss sees parallel expansions in total liabilities.
6.25%
Less than half of TRAW's 50.54%. David Dodd sees fewer share issuances vs. competitor.
-2.72%
≥ 1.5x TRAW's -1.26%. David Dodd sees higher yoy retained profits than competitor.
100.00%
Less than half of TRAW's -33.33%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-46.50%
Below half TRAW's 84.45%. Michael Burry sees potential underperformance in building shareholder capital.
-28.33%
Below half TRAW's 35.48%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.76%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
40.72%
Less than half of TRAW's -36.57%. David Dodd sees better deleveraging or stronger cash buildup than competitor.